应激相关心房颤动的发生率、危险因素与预后:VITAL-AF 试验见解
988 例新发房颤中 29% 为应激相关房颤,其抗凝启动率低于原发性房颤(56% 对 75%)。应激相关房颤与原发性房颤的不良结局风险均显著升高,应激相关房颤复合终点风险更高(HR 6.13 对 3.91)。
要点
- 新诊断房颤中近三分之一为应激相关,临床危险因素谱与原发性房颤相似。
- 应激相关房颤 90 天内抗凝启动率显著低于原发性房颤,存在治疗不足。
- 应激相关房颤复合终点(大出血、卒中、全因死亡)风险高于无房颤和原发性房颤。
核心结论
- 在超过 3 万例初级保健患者中,近三分之一的新发房颤为应激相关房颤,其不良结局风险与原发性房颤相当甚至更高,但抗凝启动率更低。
研究设计与样本
- 研究设计为 VITAL-AF 试验的事后分析,该试验为 2018 至 2019 年开展的实用性、整群随机房颤筛查试验。
- 所有参与者均接受纵向随访,对判定后的新发房颤事件(应激相关或原发性)及临床结局进行分析。
主要发现
- 988 例新发房颤中 290 例(29%)为应激相关房颤。
- 年龄、高血压、心力衰竭等临床危险因素与原发性房颤和应激相关房颤的关联相似。
- 新诊断房颤后 90 天内口服抗凝药启动率:应激相关房颤为 56%,原发性房颤为 75%,P<0.001。
- 复合终点(大出血、卒中、全因死亡)发生率:无房颤为 2.30/100 人年,原发性房颤为 15.09/100 人年,应激相关房颤为 22.71/100 人年。
- 校正后以无房颤为参照,原发性房颤 HR 为 3.91(95%CI 2.89-5.28),应激相关房颤 HR 为 6.13(95%CI 4.31-8.72)。
关键数值与推荐
- 应激相关房颤定义为在可逆性生理应激背景下新诊断的房颤。
- 校正模型纳入 CHA₂DS₂-VASc 评分、ATRIA 出血评分及时间依赖性口服抗凝暴露。
- 竞争风险模型以死亡和另一种房颤类型为竞争事件,采用 Fine-Gray 模型比较危险因素关联。
临床怎么用
- 应激相关房颤不良预后风险高但抗凝启动不足,临床应同等重视此类患者的抗凝评估与管理。
- 对于应激背景下新诊断的房颤患者,不应仅因应激可逆而忽视卒中预防和长期随访。
局限性
- 研究人群以白人为主、来自单一医疗体系,结果外推至其他人群需谨慎。
- 应激相关房颤的定义和判定依赖病历记录,可能存在分类偏倚。
- 观察性分析无法排除未测量的混杂因素对抗凝启动和结局关联的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stressor-associated atrial fibrillation (AF), defined as newly diagnosed AF in the setting of a reversible physiological stressor, is common. However, risk factors, outcomes, and current management practices remain poorly understood. METHODS: We analyzed data from VITAL-AF, a pragmatic, cluster-randomized AF screening trial conducted in 2018 and 2019 comprising adults ≥65 years of age across 16 primary care practices affiliated with Massachusetts General Hospital. All participants had longitudinal follow-up for adjudicated incident AF (including whether stressor-associated versus nonstressor-associated ["primary"]) and clinical outcomes. We compared associations between clinical AF risk factors and incident AF group (stressor-associated versus primary) using Fine-Gray models handling death and each AF group as competing risks. We also quantified oral anticoagulant initiation rates after AF diagnosis. We then fit Cox proportional hazards models to quantify associations between incident AF group (as a time-varying covariate) and a composite end point of major bleeding, stroke, and all-cause mortality, with adjustment for CHA₂DS₂-VASc (congestive heart failure, hypertension, age >74, diabetes, stroke or transient ischemic attack or thromboembolism, vascular disease, age 65-74, sex category; stroke) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation; bleeding) scores and time-varying oral anticoagulant exposure. RESULTS: We analyzed 30 265 patients (41% men, 83% White, and mean age 74 years). Of 988 incident AF events, 290 (29%) were stressor associated. Clinical risk factors, including age, hypertension, and heart failure, showed similar associations with both primary and stressor-associated AF. Oral anticoagulant initiation within 90 days of new AF diagnosis was lower for stressor-associated versus primary AF (56% versus 75%, P<0.001). The incidence of the composite end point was 2.30 per 100 person-years (95% CI, 2.17-2.44) for no AF, 15.09 (95% CI, 12.22-18.42) for primary AF, and 22.71 (95% CI, 16.91-29.87) for stressor-associated AF. In adjusted models and using no AF as the referent, both primary AF (hazard ratio [HR], 3.91 [95% CI, 2.89-5.28]) and stressor-associated AF (HR, 6.13 [95% CI, 4.31-8.72]) were associated with substantially higher risk of the composite end point. CONCLUSIONS: Among >30 000 primary care patients with adjudicated AF events, nearly one-third of incident AF cases were stressor associated. Despite similar risk factor profiles and comparably high rates of adverse outcomes, oral anticoagulant initiation is lower when AF is stressor associated. Future work is needed to define optimal approaches to prevention, surveillance, and management of stressor-associated AF.
引用
- Haimovich, Kany, Chang, et al. Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial. Circulation. 2025. PMID: 41662456. doi:10.1161/CIRCULATIONAHA.125.076421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。